Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal COVID-19 treatment trial pulled before it began

NCT ID NCT05552625

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test TADIOS, a blend of three herbs used in traditional Asian medicine, as an add-on treatment for adults hospitalized with mild to moderate COVID-19. Participants would have received TADIOS or a placebo for up to 10 days. The goal was to see if TADIOS could improve recovery and reduce inflammation. However, the trial was withdrawn before enrolling anyone, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TADIOS (a combination of three herbs traditionally used for respiratory issues in Asia)
What this could lead to
If it had worked, TADIOS might have helped reduce inflammation and speed recovery from mild to moderate COVID-19.
What could go wrong
The trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness exist. Herbal supplements can vary in quality and may interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Expected to start

May 2021

An estimate. Start dates often move.

Expected to finish

Feb 2022

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female, aged between 18 to 65 years (both inclusive) 2. Confirmed Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first infection by a reverse transcription polymerase chain reaction (RT-PCR) assay in nasal swab or oropharyngeal swab samples. 3. Patients who are hospitalized into designated hospital for COVID-19 treatment 4. Patients who can be treated within 24 hours after confirmed diagnosis with COVID-19 5. Patients with mild COVID-19 or moderate COVID-19 according to clinical management guideline of Government of India. * Mild Illness: Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as fever, cough, sore throat, nasal congestion, malaise, and headache. The elderly may present with atypical symptoms. These patients do not have any signs of dehydration, sepsis or shortness of breath. * Moderate Illness: Patient with pneumonia and no signs of severe pneumonia (Chest X-ray will be performed to rule out pneumonia in the suspected subjects). 6. Patients who have signed the written informed consent form approved by Ethics Committee to participate after understanding explanations regarding the study 7. Those who can comply with the requirements and processes in the clinical study 8. Women of childbearing age must be negative to urine pregnancy test during screening Exclusion Criteria: 1. Patients with severe COVID-19 2. Self-reported history of meaningful circulatory, renal, gastrointestinal, liver, endocrinal, hematological, or mental disease, or other serious diseases or alcohol or drug addiction that may cause safety issues or confusion in the interpretation of clinical research results by the principal investigator's judgment 3. Female patients who are pregnant (confirmed through urine pregnancy test) or breastfeeding 4. Patients with cardiovascular, liver, cancer and kidney disease. 5. Self-reported patients being a recipient of immunosuppressive therapy 6. Self-reported patients who are allergic to this dietary supplements 7. Patients taking a health functional food or medicine that may affect the body's antioxidant, anti-inflammatory activity, and lungs within 6 weeks of the first visit 8. Patients who participated in another clinical trial within 1 month before screening 9. Patients have any condition that in the judgement of investigator make the subject inappropriate for entry into this study 10. Patients consuming any herbal medicine 11. Self-reported patients with cases of surgical menopause (hysterectomy, oophorectomy of both ovaries) or sterilization procedures (tubal ligation or tubectomy of both fallopian tubes). Menopause refers to 1 year of no menstruation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chaitanya Hospital

    Paravūr, Kerala, 683513, India

  • Gunjkar Multispeciality Hospital

    Pune, Maharashtra, 4110019, India

  • Lakshmi Nursing Home

    Kochi, Kerala, 683101, India

  • Oxycare Multispecialty Hospital

    Pune, Maharashtra, 411033, India

  • Sparsh Superspeciality Hospital

    Bangalore, Karnataka, 560022, India

  • Vagus Super Specialty Hospital

    Bangalore, Karnataka, 560003, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.